

# European Drug Regulator Slaps Safety Warning on J&J Jab Due to Blood-Clot Links

By [Zero Hedge](#)

Global Research, April 21, 2021

[Zero Hedge](#) 20 April 2021

Region: [Europe](#)

Theme: [Science and Medicine](#)

All Global Research articles **can be read in 51 languages by activating the “Translate Website”** drop down menu on the top banner of our home page (Desktop version).

\*\*\*

*While Europe grapples with its own vaccine safety scandal, the EMA, the same EU pharma regulator that has insisted that the AstraZeneca-Oxford jab’s benefits far outweigh its risk, has just poured cold water on J&J’s vaccine.*

Although the EMA said the reported combination of blood clots and low blood platelets is very rare, and the overall benefits of J&J’s COVID-19 Vaccine Janssen in preventing COVID-19 outweighs the risks of side effects, the EMA has decided to affix a safety warning to the J&J jab – a warning that EMA neglected to impose on the AstraZeneca jab that is so critical to the Continent’s vaccination program.

EMA’s safety committee ([#PRAC](#)) recommends adding ‘very rare cases of unusual blood clots with low blood platelets’ to the list of side effects for Janssen [#vaccine](#).

Overall benefit-risk remains positive.

<https://t.co/hNusE5blWm> [pic.twitter.com/5kX1ECgogz](https://pic.twitter.com/5kX1ECgogz)

— EU Medicines Agency (@EMA\_News) [April 20, 2021](#)

EMA says its safety committee concluded a warning about unusual blood clots with low platelets should be added to product information for J&J [#covid19](#) vaccine, and that the events should be listed as very rare side effects of the vaccine: <https://t.co/IEuPm36R3R>

— Meg Tirrell (@megtirrell) [April 20, 2021](#)

EMA notes it confirms the overall benefit-risk of the J&J [#covid19](#) vaccine remains positive. Notes it considered all currently available evidence of unusual clots, including 8 reports from the US.

— Meg Tirrell (@megtirrell) [April 20, 2021](#)

The EMA's safety committee, known as PRAC, determined that blood clots caused by the vaccine occurred mostly at unusual sites such as in veins in the brain (cerebral venous sinus thrombosis, CVST) and the abdomen (splanchnic vein thrombosis) as well as in the arteries. They're often accompanied with low levels of blood platelets and sometimes bleeding. The cases reviewed were very similar to the cases that occurred with the COVID-19 vaccine developed by AstraZeneca, Vaxzevria, the committee said.

Healthcare professionals and people who will receive the vaccine "should be aware of the possibility of very rare cases of blood clots combined with low levels of blood platelets occurring within three weeks of vaccination," the committee added.

Mirroring comments from a top CDC doctor delivered at a press conference in the US last week which was called to discuss the blood clots tied to J&J, the PRAC said the blood clots were likely an autoimmune response to the jab. The response mirrors the reaction sometimes seen in patients treated with heparin, a blood-thinning agent, which is called heparin induced thrombocytopenia. Questions about the AstraZeneca jabs' link to these dangerous blood clots led US authorities to halt its Phase 3 trial for more than a month.

It's believed that the roots of the problem lie in the adenovirus platform upon which both J&J and AstraZeneca jabs were built.

The PRAC said it would make "further recommendations" about the J&J jab's safety once it finally finishes its accelerated safety review. Meanwhile, J&J jabs remain on hold in the US.

\*

Note to readers: please click the share buttons above or below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

*Featured image is from Children's Health Defense*

The original source of this article is [Zero Hedge](#)  
Copyright © [Zero Hedge](#), [Zero Hedge](#), 2021

---

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Zero Hedge](#)

**Disclaimer:** The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long as the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)

[www.globalresearch.ca](http://www.globalresearch.ca) contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted

material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)